Roche has entered into a definitive agreement to acquire Promedior, Inc. in a transaction valued at $1.39 billion. Roche will obtain full rights to Promedior’s entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Promedior, a privately held clinical-stage biotechnology company based in Lexington, MA, has successfully advanced PRM-151 in human clinical trials and received Breakthrough Therapy Designation from the FDA earlier this year for idiopathic pulmonary fib...